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Vaccination against yellow fever is effective, but available live virus vaccines are not recommended for use in immunocompromised
or elderly patients. We report the successful and uneventful immunization of a 62-year-old man with a history of allogeneic bone
marrow transplant and discuss evidence for this recommendation.
Vaccination against yellow fever is a simple andeffective method to protect travelers to or residents
of endemic regions. The 17D yellow fever vaccine (YF-
VAX, Aventis Pasteur, Swiftwater, PA, USA) available
in the United States is composed of live attenuated
virus; consequently, it is usually contraindicated in
immunocompromised or elderly patients.1 We report
the successful and uneventful immunization of a 62-
year-old man with a history of allogeneic bone marrow
transplant for chronic myelogenous leukemia (CML)
9 years earlier. This is the second case report of
safe vaccination with this vaccine in a bone marrow
transplant recipient and the first report in one above
60 years of age.
Case Report
The patient is a 62-year-old gentleman who was diag-
nosed with CML in October 1996. He was admitted
later that month for tumor lysis syndrome and was
treated with hydroxyurea, intravenous hydration, and
allopurinol. Bone marrow biopsy confirmed CML,
chronic phase, and cytogenetics confirmed the pres-
ence of the Philadelphia chromosome. He received a
6/6 human leukocyte antigen-matched unrelated donor
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transplant on March 20, 1997 and engrafted on day 16.
His post-transplant course was complicated by Strep-
tococcus sanguis bacteremia and cellulitis of the right
foot that resolved completely on intravenous antibiotic
therapy.
Bone marrow biopsy performed 1 year after trans-
plantation showed a complete cytogenetic remission
with marrow cellularity of 20% and no evidence of
leukemia. Standard post-transplant immunosuppression
was discontinued on September 15, 1997. During the
years that followed, he experienced several episodes
of bronchitis and developed xerophthalmia due to
chronic graft-versus-host disease (GVHD); however,
no immunosuppression was necessary. He received
immunizations with inactivated influenza virus vaccine
beginning in 1998 and polyvalent pneumococcal capsu-
lar vaccine in 1999. In spite of the latter, he developed
invasive pneumococcal pneumonia in 2001. He received
hepatitis A and B and diphtheria–tetanus vaccinations
in 2005 without incident.
In August 2005, he was referred to the University
of Michigan Overseas Travel Clinic to prepare for a 2-
week birdwatching trip in the rainforests of Eastern
Ecuador, an area endemic for yellow fever. At the
time of this evaluation, his only symptoms were those
of mild asthma; xerophthalmia had resolved 6 months
previously. Clinically, he had no evidence of GVHD
or recurrent malignancy (ie, quantitative real-time
polymerase chain reaction for BCR-ABL was negative).
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His medications at the time of presentation included
glucosamine and inhaled fluticasone.
After an extensive discussion about the possible risks
of yellow fever vaccination following bone marrow
transplantation, the patient remained convinced that the
benefits outweighed the risks given his planned travel
to Ecuador. As a crude evaluation of his capacity to
respond to new immunogens, we confirmed that he had
successfully developed antibodies to hepatitis A virus
after having received the vaccine 1 month previously.
We then administered yellow fever vaccine (17D-204
strain, YF-VAX, Aventis Pasteur, Swiftwater, PA, USA)
to him on May 16, 2006. No evidence of local or systemic
adverse effects was noted or reported during his clinic
visit or by telephone follow-up 7 days post-vaccination.
Plaque-reduction neutralization testing performed at
the Centers for Disease Control and Prevention (CDC)
6 weeks later yielded a neutralizing antibody titer of
1:1280. A titer of 1:20 is considered protective at CDC.
The patient subsequently traveled to the Ecuadorian
rainforest without any consequence to his health. He
remains well 14 months post-YF vaccination.
Discussion
Guidelines from the United States, Canada, and Europe
advise that live vaccines are contraindicated in solid
organ transplant patients for the first 2 years following
transplant or in those on continuing immunosuppressive
therapy.2–4 In bone marrow or hematopoietic stem
cell transplant patients, the same interdictions apply;
however, live vaccines are also contraindicated in
patients with acute GVHD and those with recurrent
malignancy.5 Most travel medicine authorities advise
immunosuppressed patients to avoid yellow fever
endemic regions altogether or provide letters of
exception when there is an entry requirement but
little or no actual risk of exposure.6 There is only
one previous case report of successful YF vaccination
in an allogeneic bone marrow transplant in a 50-year-
old male patient with multiple myeloma.7 This patient
tolerated the vaccine well 3 years after an allogeneic
bone marrow transplant and 2 years after discontinuing
immunosuppressive therapy. He had a positive yellow
fever serology at 2 and 9 months after vaccination.
Case reports suggest that vaccine can be given safely
to patients with human immunodeficiency virus (HIV)
without significant immunosuppression;8 however, a
fatal reaction was reported in a previously undiagnosed
HIV patient with high viral load, found to have a CD4
count of 108 cells/mm3.9
Older adults who contract wild-type yellow fever
virus have the highest risk of morbidity and mortality.10
Vaccination in elderly persons also has risks, as advanced
age and immune senescence seem to be associated
with yellow fever vaccine-associated neurotropic disease
(YEL-AND) and yellow fever vaccine-associated vis-
cerotropic disease (YEL-AVD).10–12 For this reason,
it has been suggested that yellow fever vaccine should
be contraindicated in patients above 60 years of age;
however, this remains an area of controversy.13,14
Our patient was 10 years post-bone marrow trans-
plant without recurrent malignancy, GVHD, or ongo-
ing immunosuppressive therapy. He was adamant about
traveling to the Napo region of Ecuador, which is
endemic for YF. We discussed with him the lim-
ited data available and uncertainty to fully understand
the risk of YF vaccination in post-transplant patients.
However, available data do suggest the risk of illness
and death from YF in a healthy, non-immunized per-
son taking a 2-week trip to an YF endemic area in
South America is approximately 5 per 100,000 and 1
per 100,000, respectively.1 Additionally, the risk for
YEL-AND is approximately 0.4 per 100,000 doses of
vaccine distributed and the risk of YEL-AVD is approx-
imately 0.3–0.5 cases per 100,000 doses of vaccine
distributed.1,15 Although lower than the risk for illness
and death from natural YF infection, these risks of
serious vaccine-related adverse effects increase in trav-
elers over the age of 60 and have been reported at 4
per 100,000 doses in patients aged 60–69 and 7.5 per
100,000 doses for people over 70 years of age.15 When
presented with this data, our patient felt comfortable
that his relative benefits outweighed his potential risks
and he opted for YF vaccination. He was immunized at
62 years of age.
Our patient had two potential contraindications
to YF vaccination. Based on his favorable transplant
outcome, his documented responsiveness to a killed
vaccine, his general good health, and his unshakable
desire to visit an endemic region, we concluded that
the potential benefits of YF vaccination outweighed
the possible risks. Decisions to vaccinate with yellow
fever vaccine in the post-transplant setting should be
individualized, taking into account the risk of potential
adverse events based on the patient’s immune status and
potential exposure to wild-type YF.
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